Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS) and MannKind (MNKD)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Apellis Pharmaceuticals (APLS – Research Report) and MannKind (MNKD – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Apellis Pharmaceuticals (APLS)
Mizuho Securities analyst Graig Suvannavejh reiterated a Hold rating on Apellis Pharmaceuticals today and set a price target of $20.00. The company’s shares closed last Wednesday at $21.55.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $31.15, implying a 39.1% upside from current levels. In a report released yesterday, RBC Capital also maintained a Hold rating on the stock with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
MannKind (MNKD)
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on MannKind today and set a price target of $11.00. The company’s shares closed last Wednesday at $3.45.
According to TipRanks.com, Folkes is a 2-star analyst with an average return of
MannKind has an analyst consensus of Strong Buy, with a price target consensus of $9.67.
